Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Montelukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 6/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | FPR1 | P21462 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | RECQL | P46063 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | ESR1 | P03372 | 1/20 | 0.87 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.87 |
| ▸ | FYN | P06241 | 1/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montelukast SCHEMBL31425566 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL9414 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL5267922 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL9415 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29840730 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29573125 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL3229836 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL4788140 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL8533560 | 0.99 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL6381434 | 0.99 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119147665-A | High performance liquid chromatography analysis method of montelukast sodium salt | 湖北午时医药研究院有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-117024340-A | Synthesis method of montelukast sodium | 迪嘉药业集团股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-114773266-B | Improved synthesis method of montelukast sodium | 牡丹江恒远药业股份有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-114773266-A | Improved synthesis method of montelukast sodium | 牡丹江恒远药业股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20260102762-A1 | TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12558312-B2 | Solid dosage form for transmucosal drug delivery | PRIMO PHARMATECH LLC (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| US-12539296-B2 | Montelukast for the treatment of erosive hand osteoarthritis | FARMALÍDER, S.A. (ES) | 2026-02-03 | — | — | US | disclosed |
| US-12539508-B2 | Tri-(adamantyl) phosphines and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4633613-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH S.A. (ES) | 2025-10-22 | — | — | EP | disclosed |
| US-20220251136-A1 | MONTELUKAST ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | GENETIC S.P.A. (IT) | 2022-08-11 | — | — | US | disclosed |
| EP-4032535-A1 | PHARMACEUTICAL COMPOSITION | University of Fukui (JP) | 2022-07-27 | — | — | EP | disclosed |
| CN-114773266-A | Improved synthesis method of montelukast sodium | 牡丹江恒远药业股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114773266-A | Improved synthesis method of montelukast sodium | 牡丹江恒远药业股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
| CN-114650828-A | Pharmaceutical composition | 国立大学法人福井大学 | 2022-06-21 | — | — | CN | disclosed |
| US-20220047570-A1 | MONTELUKAST FOR THE TREATMENT OF EROSIVE HAND OSTEOARTHRITIS | FARMALIDER, S.A. (ES) | 2022-02-17 | — | — | US | disclosed |
| CN-114010609-A | Montelukast sodium freeze-dried orally disintegrating tablet and preparation method thereof | 莱默(北京)药业科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | CYSLTR1 574/4885CYSLTR2 833/4885CYP2C8 103/4885 |
| US-12558312-B2 | Solid dosage form for transmucosal drug delivery | AANAT, MTNR1B, CHLSN | CYSLTR1 764/4885CYSLTR2 672/4885CYP2C8 2646/4885 |
| US-12539508-B2 | Tri-(adamantyl) phosphines and applications thereof | OTC, AOC3, ICOSLG | CYSLTR1 4727/4885CYSLTR2 4735/4885CYP2C8 2567/4885 |
| US-20260102762-A1 | TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF | PTMS, TEC, CD2 | CYSLTR1 3720/4885CYSLTR2 3790/4885CYP2C8 1443/4885 |
| US-12539296-B2 | Montelukast for the treatment of erosive hand osteoarthritis | MMP9, SOST, MMP14 | CYSLTR1 142/4885CYSLTR2 153/4885CYP2C8 2780/4885 |
| US-20220251136-A1 | MONTELUKAST ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TSLP, LTC4S, CMA1 | CYSLTR1 6/4885CYSLTR2 16/4885CYP2C8 828/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | CYSLTR1 24/4885CYSLTR2 25/4885CYP2C8 1945/4885 |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | CYSLTR1 1407/4885CYSLTR2 697/4885CYP2C8 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.